Reyes-Capo Daniela P, Yannuzzi Nicolas A, Smiddy William E, Flynn Harry W
Ophthalmic Surg Lasers Imaging Retina. 2021 Jun;52(6):319-326. doi: 10.3928/23258160-20210528-04. Epub 2021 Jun 1.
To report the incidence and clinical features of infectious endophthalmitis after intravitreal (IV) injection of anti-vascular endothelial growth factor inhibitors (VEGF) between 2018 and 2020 and to compare to prior rates.
Retrospective analysis of patients with endophthalmitis after anti-VEGF IV injections treated at Bascom Palmer Eye Institute between January 1, 2018, and December 31, 2020.
Between 2018 and 2020, the rate of clinically diagnosed endophthalmitis was 0.014% (10/71,858) and of culture-positive was 0.008% (6/71,858). Clinically diagnosed endophthalmitis rates per injection were: aflibercept (0.022%); ranibizumab (0.019%); bevacizumab (0%); and brolucizumab (0%). Clinically diagnosed endophthalmitis rates were similar in the present study compared to those from 2005 to 2017 ( = .84). Fifteen eyes were diagnosed with endophthalmitis (10 in-house, five external referrals). Of culture-positive eyes, the organisms were coagulase-negative (8/11), species (2/11), and (1/11). A universal face-masking policy in 2020 did not lower infection rates ( = .73).
Endophthalmitis rates after IV anti-VEGF remain low and are similar to prior reports. .
报告2018年至2020年间玻璃体内注射抗血管内皮生长因子抑制剂（VEGF）后感染性眼内炎的发生率和临床特征，并与先前的发生率进行比较。
回顾性分析2018年1月1日至2020年12月31日在巴斯科姆·帕尔默眼科研究所接受抗VEGF玻璃体内注射治疗后发生眼内炎的患者。
2018年至2020年间，临床诊断的眼内炎发生率为0.014%（10/71,858），培养阳性率为0.008%（6/71,858）。每次注射的临床诊断眼内炎发生率分别为：阿柏西普（0.022%）；雷珠单抗（0.019%）；贝伐单抗（0%）；和布罗达单抗（0%）。与2005年至2017年的研究相比，本研究中临床诊断的眼内炎发生率相似（P = 0.84）。15只眼被诊断为眼内炎（10只为本院治疗，5只为外部转诊）。在培养阳性的眼中，病原体为凝固酶阴性葡萄球菌（8/11）、链球菌属（2/11）和其他（1/11）。2020年的通用面部遮盖政策并未降低感染率（P = 0.73）。
玻璃体内注射抗VEGF后的眼内炎发生率仍然较低，与先前的报告相似。
